Yanhong Deng, M.D.
Sixth Affiliated Hospital, Sun Yat-sen University
8
8
2
N/A
0
5
Research Impact
N/A
Research impact score
0
Total publications
0
Published trial results
0
Total citations
Drug Portfolio
+7 more interventions
Analytics
Trial Phases
Trial Status
Role Distribution
Activity Timeline
Clinical Trials (8)
Research Network
Collaboration Network
Research Areas & Affiliations
Therapeutic Areas
Affiliations
Similar Key Opinion Leaders
Discover other key opinion leaders with similar research profiles, therapeutic areas, and collaboration networks.
Norman Wolmark, MD
NSABP Foundation Inc
Shared therapeutic areas:
Sabine Hazan, MD
ProgenaBiome
Shared therapeutic areas:
Steven A Rosenberg, M.D.
National Cancer Institute (NCI)
Shared therapeutic areas:
Eric FRANCOIS, Dr
Centre Antoine Lacassagne, Nice
Shared therapeutic areas:
David Cunningham
Royal Marsden NHS Foundation Trust
Shared therapeutic areas:
howard Safran, MD
Brown University
Shared therapeutic areas:
Ajay Goel, PhD
City of Hope Medical Center
Shared therapeutic areas:
yuankai shi, MD
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Shared therapeutic areas:
Tim F Greten, M.D.
National Cancer Institute (NCI)
Shared therapeutic areas:
Shivan Mehta, MD
University of Pennsylvania
Shared therapeutic areas:
Publications (0)
No publications found for this investigator.
Clinical Trials (8)
Showing 8 of 8 trials
Bevacizumab Plus mFOLFOXIRI as First-line Treatment for Patients With Unresectable Metastatic Colorectal Cancer
Regorafenib and PD-1 Antibody in Combination With Radiotherapy for pMMR/MSS Metastatic Colorectal Cancer
Neoadjuvant Toripalimab With or Without Celecoxib in dMMR/MSI-H Colorectal Cancer
PD-1 Antibody Combined With COX Inhibitor in MSI-H/dMMR or High TMB Colorectal Cancer
FOLFOXIRI With or Without Bevacizumab as First-line Treatment for Unresectable Liver-only Metastatic Colorectal Cancer Patients With RAS Mutation-type
FOLFOX or CAPOX Perioperative Chemotherapy Versus Postoperative Chemotherapy for Locally Advanced Colon Cancer (OPTICAL)
FOLFOXIRI With or Without Cetuximab as First-line Treatment of Patients With Non-resectable Liver - Only Metastatic Colorectal Cancer
FOLFOXIRI Compared to FOLFOX in First Line Treatment of Metastatic Colorectal Cancer
All 8 trials loaded